NR, milstone achieved with HematechLAVAL, QUEBEC--(Marketwired - Jan. 22, 2014) - ProMetic Life Sciences Inc. (PLI.TO)(PFSCF), ("ProMetic" or the "Corporation") announced today the achievement of the second manufacturing milestone related to its strategic agreement ("Agreement") with Hematech Biotherapeutics Inc. ("Hematech") triggering a $1.0 million payment to ProMetic. This milestone was achieved following the successful completion of the first large-scale production run at its ProMetic BioProduction Inc. ("PBP") plasma purification facility located in Laval, Quebec. "The remarkable performance of ProMetic's manufacturing process has been further confirmed with the biopharmaceuticals produced in ProMetic's facility meeting the targeted product specifications", stated Dr. Chan, Chairman of Hematech. "We are looking forward to this proprietary manufacturing process being operational in our own facility in Taipei", added Dr. Chan. The Agreement with Hematech calls for additional milestone payments in 2014 in relation to the filing of Investigational New Drug ("IND") applications for two plasma-derived biopharmaceuticals to be manufactured in ProMetic's facility. Mr. Pierre Laurin, ProMetic's President and Chief Executing Officer commented: "The achievement of this manufacturing milestone was critical for the advancement of the plasminogen and other plasma derived therapeutics respective clinical trial programs".